The Fifth World Leishmaniasis Congress was organized by the Oswaldo Cruz Foundation, the Brazilian Society of Tropical Medicine, the Brazilian Society of Protozoology, and the Brazilian Society of Parasitology.
Click here to read more about World Leish 5.
Translation from WHO Recommendation to Implementation in National Policy
Ellis S, Musa AM, Burza S, Alirol E, Lima MA, Chappuis F, Hailu A, Khalil E, Olobo J, Strub N, Wasunna M, Sharma B, Balasegaram M
Asymptomatic infections, the experience from the Indian subcontinent
Towards the identification of a back-up candidate for DNDI-VL-2098 to treat visceral leishmaniasis
Delphine Launay, Eric Chatelain, Stéphanie Braillard, Suman Gupta, Sunil Puri, Vanessa Yardley, Louis Maes, Patrick O’Connor, Andrew Marshall, Andrew Thompson
DNDI-VL-2098: a nitroimidazooxazole as clinical candidate to treat visceral leishmaniasis
Delphine Launay, Denis Martin, Anne-Sophie Bessis, Stéphanie Braillard, Preeti Vishwakarma, Suman Gupta, Sunil Puri, Vanessa Yardley, Mukkavilli Rao, Vikram Ramanathan, Haladasappa Krishnappad, Hari Pati, Andrew Thompson
Development of new drugs for Leishmaniasis: what can we learn from the in vivo profiling of several promising chemical series
Stéphanie Braillard, Eric Chatelain, Charles E. Mowbray, Delphine Launay, Louis Maes, Andrew Thompson
Click here for more information on DNDi‘s approach to developing drugs against Leishmaniasis.